Loading…
Japanese drugstore chain selling over-the-counter medicines, cosmetics and daily goods across the country.
Japanese drugstore chain selling over-the-counter medicines, cosmetics and daily goods across the country.
Earns the mark-up between buying and shelf prices on a wide range of low-priced goods, where food and daily necessities draw traffic to stores that also carry medicines and cosmetics. In-store dispensing adds prescription income, paid largely through Japan's public health insurance.
In one line: A Japanese CVS/Walgreens.
Moat: narrow (scale, distribution). Large nationwide drugstore network scale in a consolidating Japanese retail-pharmacy industry.
Headquarters: Tokyo, Japan · Founded: 1958 · Employees: 7,457
Size Sundrug (9989.T) is a Japan Consumer Staples company (Drugstore Chains) with a market value of $2.77B, the 384th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥3,739 on 6 Nov 2026.
Performance Over six months the shares fell 0.9%, against +6.6% for the median peer and +1.8% for the Japan market (cap-weighted) — 6th lowest of 15 in its peer set.
Growth Revenue grew 4.3% over the last twelve months (peer median +8.8%); the operating margin is 5.5% (peer median 4.8%).
Valuation It trades at 13.3× forward earnings against a peer median of 16.9× (cheapest of 12).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.9 points above its cost of capital (5.0% WACC).
Next results Next results expected around 13 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥850B | ¥843B | ¥802B | ¥752B | ¥690B |
| Revenue growth | — | +5% | +7% | +9% | — |
| Gross profit | ¥218B | ¥197B | ¥187B | ¥189B | ¥172B |
| EBITDA | ¥65.8B | ¥65.7B | ¥61.9B | ¥56.2B | ¥49.5B |
| Net income | ¥31.5B | ¥31.4B | ¥30.8B | ¥29.1B | ¥25.7B |
| Free cash flow | n/a | ¥13.0B | ¥7.71B | ¥4.76B | ¥12.6B |
| Capital expenditure | n/a | ¥31.1B | ¥34.3B | ¥38.2B | ¥26.1B |
| Total debt | ¥48.0B | ¥49.0B | ¥39.5B | ¥35.9B | ¥939M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sundrug 9989.T | $2.77B | -1% | +4% | 5% | 13.3× | -8.0% |
| Sugi 7649.T | $3.27B | -23% | +9% | 5% | 16.8× | -9.7% |
| Ain 9627.T | $1.23B | -2% | +42% | 4% | 13.4× | -6.5% |
| COSMOS Pharmaceutical 3349.T | $3.20B | +5% | +9% | 4% | 15.7× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 9989.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.6% | +6.1% | 8th highest of 15 |
| 6-month return | -0.9% | +6.6% | 6th lowest of 15 |
| Distance from 52-week high | -16.3% | -18.9% | 7th highest of 15 |
| Revenue growth (TTM) | +4.3% | +8.8% | 3rd lowest of 15 |
| Operating margin | 5.5% | 4.8% | 6th highest of 15 |
| Forward P/E | 13.3× | 16.9× | cheapest of 12 |
| Growth the price implies (Req g, 7 yrs) | -8.0% | -6.5% | 7th least demanding of 14 |
| Growth delivered (Del g) | +5.8% | +13.6% | lowest of 14 |
| Hurdle (Req g minus delivered) | -13.8 pp | -20.6 pp | 5th most demanding of 14 |
| ROIC minus cost of capital | +6.9 pp | +7.6 pp | 7th lowest of 15 |
| EV / EBITDA | 6.4× | 7.9× | 3rd cheapest of 9 |
| Net debt / EBITDA | -0.2× | 0.0× | 5th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sundrug 9989.T | Japan | $2.77B | -1% | +4% | 5% | 13.3× | -8.0% | +5.8% |
| Guardian Pharmacy Services GRDN | United States | $2.68B | +17% | +10% | 6% | 30.6× | 4.1% | +16.8% |
| Sugi 7649.T | Japan | $3.27B | -23% | +9% | 5% | 16.8× | -9.7% | +10.9% |
| DaShenLin Pharmaceutical 603233.SS | China | $3.80B | +15% | +7% | 8% | 16.6× | -9.0% | +13.6% |
| LBX Pharmacy Chain Joint Stock 603883.SS | China | $1.69B | +7% | +3% | 5% | 16.3× | -10.9% | +9.7% |
| Yifeng Pharmacy Chain 603939.SS | China | $4.91B | +17% | +5% | 10% | 17.2× | -9.2% | +13.2% |
| Create SD 3148.T | Japan | $1.30B | -2% | +9% | 5% | n/a | -11.5% | +8.0% |
| Ain 9627.T | Japan | $1.23B | -2% | +42% | 4% | 13.4× | -6.5% | +16.9% |
| Yixintang Pharmaceutical 002727.SZ | China | $1.18B | +6% | -2% | 3% | 16.9× | -15.9% | +6.5% |
| TSURUHA 3391.T | Japan | $6.74B | +15% | +114% | 4% | 22.2× | -2.3% | +9.6% |
| MatsukiyoCocokara & 3088.T | Japan | $6.78B | +17% | +5% | 8% | 17.5× | -6.2% | +15.5% |
| Shu Yu Civilian Pharmacy 301017.SZ | China | $872M | +9% | +9% | 2% | n/a | 4.0% | +17.4% |
| Anhui Huaren Health Pharmaceutical 301408.SZ | China | $829M | -35% | +15% | 8% | n/a | -6.0% | +23.3% |
| MedPlus Health Services MEDPLUS.NS | India | $769M | -31% | +21% | 4% | 35.1× | 18.5% | +17.6% |
| Genky DrugStores 9267.T | Japan | $723M | +3% | +8% | 5% | 13.7× | n/a | n/a |